Betting on BTK Inhibitors in CLL: Where are We Now and Where are We Going?
This initiative is targeted to addressing the professional practice of pharmacists in hospitals, health systems, ambulatory care clinics, and other settings. Attendees of this activity will gain insight into the latest clinical and scientific advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKis), including the latest approvals, the most current safety and efficacy data, and expert insights into addressing challenges of CLL treatment using BTKis. Using a case-based approach, discussion on anticipating and managing adverse events, therapy selection, and improving adherence will be incorporated into this cutting-edge activity.
Supported by an independent educational grant from AstraZeneca.
This activity is designed to meet the educational needs of hospital and health-system pharmacists, pharmacy directors, and pharmacy residents.
1. Describe the role of the BCR (B-cell receptor) pathway in malignant B-cell survival.
2. Explore the therapeutic rationale for targeting the BCR pathway in CLL and other B-cell malignancies.
3. Assess the latest safety and efficacy data for BTKis (BTK inhibitors) in TN (treatment-naïve) and R/R (relapsed/refractory) CLL and examine strategies to overcome resistance seen in these agents.
4. Using a case-based approach, appraise effective strategies to integrate BTK inhibitors into the CLL treatment paradigm, recognize and appropriately manage adverse events, and answer challenging clinical issues pharmacists may encounter in their practice.
5 min Welcome and Introductions/Pre-test
10 min The BCR Pathway: A Potential Game-Changing Target in CLL
20 min Addressing Challenges in CLL Treatment: BTK Inhibition-the Past, Present, and Future
15 min Pharmacist Perspectives: Exploring Current Challenges in CLL Management and Integrating BTKis into Practice
10 min Q&A/Post-test
Emily K. Dotson, PharmD, BCOP
Clinical Pharmacist Specialist–Hematology Lead
The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
The Ohio State University
Emily Dotson, received her PharmD from St. Louis College of Pharmacy. She completed a PGY1 residency at the Richard L. Roudebush VA Medical Center in Indianapolis, IN and then a PGY2 residency at The James Cancer Hospital in Columbus, OH. After completion, she stayed at The James where she serves as a Clinical Pharmacist, rotating between outpatient and inpatient services. Dr. Dotson's area of practice is in chronic lymphocytic leukemia (CLL), Non-Hodgkin lymphoma, and Hodgkin lymphoma patients, and she also serves as the Hematology Lead Pharmacist. She is actively involved in research projects with the lymphoma and CLL teams and is a preceptor to pharmacy students and pharmacy residents.
Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Vanessa Carranza–has no relevant financial relationships to disclose in relation to the content of this activity.
Emily K. Dotson, PharmD, BCOP–has disclosed that she is a consultant for AstraZeneca.
Kathy Hogan Edwards, PharmD, BCPS, BCOP–has disclosed that she is a consultant for Genzyme Corporation.
Stephen E. Spurgeon, MD–has disclosed that he is a consultant for Janssen and Portola Pharmaceuticals. He receives grant/research support from Acerta, AstraZeneca, Bristol Myers Squibb, Genentech, Janssen, and Velos-Bio.
Benyam Muluneh, PharmD, BCOP, CPP–has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This application-based activity is approved for 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit JA0007101-0000-20-001-L01-P
Upon completion of a CE request form, pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 Participation